Potential synergistic effects of sorafenib and CP‑31398 for treating anaplastic thyroid cancer with p53 mutations

  • Authors:
    • Jiin‑Torng Wu
    • Ching‑Ling Lin
    • Chi‑Jung Huang
    • Yu‑Che Cheng
    • Chih‑Cheng Chien
    • Yung‑Chuan Sung
  • View Affiliations

  • Published online on: February 7, 2020     https://doi.org/10.3892/ol.2020.11377
  • Pages: 3021-3026
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Thyroid cancer is the most commonly diagnosed endocrine cancer. Anaplastic thyroid cancer (ATC) is the most aggressive type of thyroid cancer and has a poor prognosis. Loss of p53 function has been reported to lead to poorly differentiated thyroid tumors; therefore, mutant p53 protein can be considered a crucial therapeutic target in patients with ATC. Sorafenib, a multi‑kinase inhibitor, has been approved for the treatment of metastatic and differentiated thyroid cancer. Combined targeted therapy, including sorafenib, may be clinically significant for patients with ATC harboring p53 mutations. In the present study, CP‑31398, a p53‑restoring agent, was used to improve the therapeutic efficacy of sorafenib in SW579 cells, an ATC cell line harboring p53 mutations. The molecular function of CP‑31398 was evaluated using western blot analysis and a luciferase reporter assay. The decreased viability of SW579 cells, following CP‑31398 treatment, was augmented by sorafenib, and CP‑31398 enhanced the antimitogenic effect of sorafenib; thus, sorafenib and CP‑31398 synergistically inhibited the growth of SW579 cells. These results indicate a potential clinical application of CP‑31398 for patients with ATC harboring p53 abnormalities, since these individuals generally respond poorly to sorafenib alone.
View Figures
View References

Related Articles

Journal Cover

April-2020
Volume 19 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wu JT, Lin CL, Huang CJ, Cheng YC, Chien CC and Sung YC: Potential synergistic effects of sorafenib and CP‑31398 for treating anaplastic thyroid cancer with p53 mutations. Oncol Lett 19: 3021-3026, 2020
APA
Wu, J., Lin, C., Huang, C., Cheng, Y., Chien, C., & Sung, Y. (2020). Potential synergistic effects of sorafenib and CP‑31398 for treating anaplastic thyroid cancer with p53 mutations. Oncology Letters, 19, 3021-3026. https://doi.org/10.3892/ol.2020.11377
MLA
Wu, J., Lin, C., Huang, C., Cheng, Y., Chien, C., Sung, Y."Potential synergistic effects of sorafenib and CP‑31398 for treating anaplastic thyroid cancer with p53 mutations". Oncology Letters 19.4 (2020): 3021-3026.
Chicago
Wu, J., Lin, C., Huang, C., Cheng, Y., Chien, C., Sung, Y."Potential synergistic effects of sorafenib and CP‑31398 for treating anaplastic thyroid cancer with p53 mutations". Oncology Letters 19, no. 4 (2020): 3021-3026. https://doi.org/10.3892/ol.2020.11377